Status:
UNKNOWN
Relevance of T Lymphocytes Tumor Infiltrates CD8 and Foxp3 as Immune Prognostic Biomarker in Breast Cancer Treated by Neo Adjuvant Chemotherapy
Lead Sponsor:
Centre Georges Francois Leclerc
Conditions:
Breast Cancer
Eligibility:
FEMALE
18-80 years
Phase:
NA
Brief Summary
Neoadjuvant chemotherapy is standard therapy for the management of localised breast cancer, and makes it possible to evaluate tumour response. Achieving pathological complete response (pCR) after chem...
Eligibility Criteria
Inclusion
- inclusion criteria
- Signed informed consent
- Social security coverage
- Age between 18 and 80 years
- Histologically proven breast cancer, regardless of histological type or molecular subtype (triple negative, hormone-receptor positive, HER2+++), including inflammatory forms
- Localised breast cancer with or without axillary or subclavicular lymph node involvement
- Absence of bone or visceral metastasis on further evaluation (bone scintigraphy, chest X-ray, abdominal echocardiography or CT scan of the thorax, abdomen and pelvic area)
- Treatment by neoadjuvant chemotherapy (treatment protocol at physician's discretion)
- Patient amenable to receiving adjuvant therapy (chemotherapy, radiotherapy, hormone therapy, targeted therapy)
- Breast surgery (breast-sparing or not) planned after neoadjuvant chemotherapy
- exclusion criteria
- Metastatic breast cancer
- Neoadjuvant radiotherapy
- Patient not amenable to surgery
- Ongoing therapy for any other type of cancer
- Legal incapacity (incarceration or persons under legal guardianship)
- Patient unable to sign the informed consent or unable to attend medical follow-up for geographical, social or mental reasons.
Exclusion
Key Trial Info
Start Date :
May 1 2012
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 1 2025
Estimated Enrollment :
500 Patients enrolled
Trial Details
Trial ID
NCT01513408
Start Date
May 1 2012
End Date
October 1 2025
Last Update
October 17 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
CGFL
Dijon, France, 21079